Form 4: Pliant Therapeutics CEO Acquires Shares Following Performance Milestone

Pliant Therapeutics' CEO, Bernard Coulie, acquired 75,625 shares of common stock after the achievement of performance criteria related to the company's total shareholder return.

Summary

• On July 9, 2024, Pliant Therapeutics' CEO, Bernard Coulie, acquired 75,625 shares of common stock.
• This acquisition was triggered by the vesting of performance-vested stock units granted on July 28, 2022.
• The vesting was contingent upon the achievement of pre-established performance criteria related to the company's total shareholder return relative to the Nasdaq Biotechnology Index.
• The Compensation Committee of the Issuer's Board of Directors certified the achievement of these performance criteria.
• Coulie also owns 1,489 shares acquired through an Employee Stock Purchase Plan.
• Additionally, 409,317 shares are held by The Coulie/Leyman Family Trust, for which Coulie and his spouse serve as trustees, but he disclaims beneficial ownership except to the extent of his pecuniary interest.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the vesting of shares indicates the achievement of performance goals, but it's a routine filing and doesn't contain groundbreaking news.

Positives

• The vesting of performance-based stock units suggests that Pliant Therapeutics has met certain performance targets related to shareholder return.
• The CEO's increased stake in the company could be seen as a positive signal to investors.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which can influence investor sentiment.

Stakeholder Impact

• Shareholders may view the vesting of shares positively, as it suggests the company is meeting its performance targets.
• Employees participating in the Employee Stock Purchase Plan benefit from the opportunity to acquire company stock.

Key Dates